{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:10:19Z","timestamp":1780665019535,"version":"3.54.1"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To elucidate the impact of left ventricular diastolic dysfunction (LVDD) on the risk of medium-term poor prognosis in patients with cirrhotic ascites.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 194 patients with cirrhotic ascites were included in this retrospective study and categorized into two groups (LVDD and non-LVDD) based on echocardiography findings. Lasso and univariate Cox regression analyses were initially used to screen potential influencing factors of 1-year mortality from basic clinical data. Multivariate Cox regression was then performed to identify independent risk factors. Kaplan\u2013Meier (K-M) and time-dependent receiver operating characteristic (ROC) curves were used to assess the predictive value of LVDD for 1-year mortality. Subgroup analysis was also conducted based on the presence or absence of hepatic malignancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"custom\">\n                        <jats:list-item>\n                          <jats:label>(1)<\/jats:label>\n                          <jats:p>LVDD was present in 47.4% (92\/194) of patients with cirrhotic ascites;<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:label>(2)<\/jats:label>\n                          <jats:p>\n                            Regression analyses (Lasso, univariate Cox, and multivariate Cox) revealed that LVDD (hazard ratio = 2.109, 95% confidence interval [1.279\u20133.478],\n                            <jats:italic>P<\/jats:italic>\n                            = 0.003) was an independent risk factor for 1-year mortality;\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:label>(3)<\/jats:label>\n                          <jats:p>\n                            Time-dependent ROC curves demonstrated that the predictive performance of LVDD for 360-day mortality, in the overall population and patients without hepatic malignancy, was comparable to that of traditional Child\u2013Turcotte\u2013Pugh (CTP) and Model for End-Stage Liver Disease (MELD) scores (\n                            <jats:italic>P<\/jats:italic>\n                            &gt; 0.05 for all).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>LVDD increases the risk of 1-year mortality in patients with cirrhotic ascites, particularly in those without hepatic malignancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/rjim-2025-0022","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:00:13Z","timestamp":1763564413000},"page":"13-24","source":"Crossref","is-referenced-by-count":0,"title":["Left Ventricular Diastolic Dysfunction Increases the Risk of Medium-term Mortality in Patients with Cirrhotic Ascites"],"prefix":"10.2478","volume":"64","author":[{"given":"Sheng-Hao","family":"Li","sequence":"first","affiliation":[{"name":"School of Public Health, School of Public Health , Dali University , no. 2, Hongsheng Road, Dali Town, Dali Bai Autonomous Prefecture , Dali City , Yunnan Province , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Public Health, School of Public Health , Dali University , no. 2, Hongsheng Road, Dali Town, Dali Bai Autonomous Prefecture , Dali City , Yunnan Province , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Juan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine , The Third People's Hospital of Kunming\/Yunnan Clinical Center for Infectious Diseases , no. 319 Wujing Road, Guandu District , Kunming City , Yunnan Province , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Li","sequence":"additional","affiliation":[{"name":"School of Public Health, School of Public Health , Dali University , no. 2, Hongsheng Road, Dali Town, Dali Bai Autonomous Prefecture , Dali City , Yunnan Province , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Min","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Public Health, School of Public Health , Dali University , no. 2, Hongsheng Road, Dali Town, Dali Bai Autonomous Prefecture , Dali City , Yunnan Province , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatology 1 , The Third People's Hospital of Kunming\/Yunnan Clinical Center for Infectious Diseases , no. 319 Wujing Road, Guandu District , Kunming City , Yunnan Province , P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"2026060512262507672_j_rjim-2025-0022_ref_001","doi-asserted-by":"crossref","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet, 2018, 392(10159): 1789\u2013858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_002","doi-asserted-by":"crossref","unstructured":"GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 245\u201366.","DOI":"10.1016\/S2468-1253(19)30349-8"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_003","doi-asserted-by":"crossref","unstructured":"D'AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies [J]. J Hepatol, 2006, 44(1): 217\u201331.","DOI":"10.1016\/j.jhep.2005.10.013"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_004","doi-asserted-by":"crossref","unstructured":"REIBERGER T, P\u00dcSP\u00d6K A, SCHODER M, BAUMANN-DURCHSCHEIN F, BUCSICS T, DATZ C, DOLAK W, FERLITSCH A, FINKENSTEDT A, GRAZIADEI I, HAMETNER S, KARNEL F, KRONES E, MAIERON A, MANDORFER M, PECK-RADOSAVLJEVIC M, RAINER F, SCHWABL P, STADLBAUER V, STAUBER R, TILG H, TRAUNER M, ZOLLER H, SCH\u00d6FL R, FICKERT P. Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III) [J]. Wien Klin Wochenschr, 2017, 129(Suppl 3): 135\u201358.","DOI":"10.1007\/s00508-017-1262-3"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_005","doi-asserted-by":"crossref","unstructured":"BENMASSAOUD A, FREEMAN SC, ROCCARINA D, PLAZ TORRES MC, SUTTON AJ, COOPER NJ, IOGNA PRAT L, COWLIN M, MILNE EJ, HAWKINS N, DAVIDSON BR, PAVLOV CS, THORBURN D, TSOCHATZIS E, GURUSAMY KS. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis [J]. Cochrane Database Syst Rev, 2020, 1(1): Cd013123.","DOI":"10.1002\/14651858.CD013123.pub2"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_006","doi-asserted-by":"crossref","unstructured":"BORAH GJ, PANDE G, MALAKAR S, KUMAR SR, YADAV RR, MOHINDRA S. Midodrine and weekly albumin therapy in patients with cirrhosis and diuretic intractable or recurrent ascites: a case-control study [J]. Cureus, 2025, 17(1): e76988.","DOI":"10.7759\/cureus.76988"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_007","doi-asserted-by":"crossref","unstructured":"WU HHL, RAKISHEVA A, PONNUSAMY A, CHINNADURAI R. Hepatocardiorenal syndrome in liver cirrhosis: recognition of a new entity? [J]. World J Gastroenterol, 2024, 30(2): 128\u201336.","DOI":"10.3748\/wjg.v30.i2.128"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_008","doi-asserted-by":"crossref","unstructured":"RAZPOTNIK M, BOTA S, WIMMER P, HOFER P, HACKL M, F\u00dcRSTNER M, ALBER H, MOHR R, WREE A, WALIA N, ENGELMANN C, DEMIR M, TACKE F, PECK-RADOSAVLJEVIC M. Development of liver-heart score for early detection of myocardial contractile dysfunction in cirrhosis by strain imaging [J]. Liver Int, 2025, 45(4): e70062.","DOI":"10.1111\/liv.70062"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_009","doi-asserted-by":"crossref","unstructured":"BARRERA N, JOU K, MALIK M, GALLEGOS-KOYNER F, CHAMAY S, ELFERT K, CERRUD-RODRIGUEZ RC, DI BIASE L. Safety of catheter ablation for atrial fibrillation in patients with liver cirrhosis [J]. J Cardiovasc Electrophysiol, 2025, 36(1): 103\u201310.","DOI":"10.1111\/jce.16472"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_010","doi-asserted-by":"crossref","unstructured":"EL KOOFY N, OKASHA SH, AGHA HM, ALI N, BEHAIRY AS, FOUAD HM, ZAWAM RH. Prevalence and predictors of pulmonary hypertension in children with portal hypertension: a single center study [J]. Pediatr Gastroenterol Hepatol Nutr, 2025, 28(2): 101\u201312.","DOI":"10.5223\/pghn.2025.28.2.101"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_011","doi-asserted-by":"crossref","unstructured":"JIA Y, LIU L, ZHOU Y, YAO Y, CHENG Y, CHENG Y, SHEN C, YANG R, ZENG R, WAN Z, ZHAO Q, LI D, YUAN B, LIAO X. Prognostic implications of cardiac geometry in cirrhosis: findings from a large cohort [J]. Liver Int, 2025, 45(2): e16230.","DOI":"10.1111\/liv.16230"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_012","doi-asserted-by":"crossref","unstructured":"LEE SK, SONG MJ, KIM SH, AHN HJ. Cardiac diastolic dysfunction predicts poor prognosis in patients with decompensated liver cirrhosis [J]. Clin Mol Hepatol, 2018, 24(4): 409\u201316.","DOI":"10.3350\/cmh.2018.0034"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_013","doi-asserted-by":"crossref","unstructured":"STUNDIENE I, SARNELYTE J, NORKUTE A, AIDIETIENE S, LIAKINA V, MASALAITE L, VALANTINAS J. Liver cirrhosis and left ventricle diastolic dysfunction: Systematic review [J]. World J Gastroenterol, 2019, 25(32): 4779\u201395.","DOI":"10.3748\/wjg.v25.i32.4779"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_014","unstructured":"[Guidelines on the management of ascites in cirrhosis (2023 version) ][J]. Zhonghua Gan Zang Bing Za Zhi, 2023, 31(8): 813\u201326."},{"key":"2026060512262507672_j_rjim-2025-0022_ref_015","doi-asserted-by":"crossref","unstructured":"NAGUEH SF, APPLETON CP, GILLEBERT TC, MARINO PN, OH JK, SMISETH OA, WAGGONER AD, FLACHSKAMPF FA, PELLIKKA PA, EVANGELISA A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography [J]. Eur J Echocardiogr, 2009, 10(2): 165\u201393.","DOI":"10.1093\/ejechocard\/jep007"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_016","doi-asserted-by":"crossref","unstructured":"FOUAD YM, YEHIA R. Hepato-cardiac disorders [J]. World J Hepatol, 2014, 6(1): 41\u201354.","DOI":"10.4254\/wjh.v6.i1.41"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_017","doi-asserted-by":"crossref","unstructured":"EL HADI H, DI VINCENZO A, VETTOR R, ROSSATO M. Relationship between heart disease and liver disease: a two-way street [J]. Cells, 2020, 9(3): 567.","DOI":"10.3390\/cells9030567"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_018","doi-asserted-by":"crossref","unstructured":"M\u00d8LLER S, BENDTSEN F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis [J]. Liver Int, 2018, 38(4): 570\u201380.","DOI":"10.1111\/liv.13589"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_019","doi-asserted-by":"crossref","unstructured":"BEHERA MK, SWAIN SN, SAHU MK, BEHERA GK, MISHRA D, NARAYAN J, SINGH A, AGARWAL S, MALLICK PK. Diastolic dysfunction is a predictor of poor survival in patients with decompensated cirrhosis [J]. Int J Hepatol, 2021, 2021: 5592376.","DOI":"10.1155\/2021\/5592376"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_020","doi-asserted-by":"crossref","unstructured":"BEHERA MK, NARAYAN J, SAHU MK, BEHERA SK, SINGH A, MISHRA D, AGARWAL S, UTHANSINGH K. Factors predicting cardiac dysfunction in patients with liver cirrhosis [J]. Middle East J Dig Dis, 2021, 13(3): 216\u201322.","DOI":"10.34172\/mejdd.2021.228"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_021","doi-asserted-by":"crossref","unstructured":"SOLANKI R, SREESH S, ATTUMALIL TV, MOHAPATRA SD, NARAYANAN V, MADHU D, CHAKRAVORTY A, PAL R, NAIR A, DEVADAS K. A case-cohort study of left ventricular diastolic dysfunction in patients with cirrhosis: the liver-heart axis [J]. Ann Gastroenterol, 2023, 36(6): 678\u201385.","DOI":"10.20524\/aog.2023.0837"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_022","doi-asserted-by":"crossref","unstructured":"N\u00d8RSKOV MP, M\u00d8NSTED T, KIMER N, DAMGAARD M, M\u00d8LLER S. Can plasma volume determination in cirrhosis be replaced by an algorithm using body weight and hematocrit? [J]. Diagnostics (Basel), 2024, 14(8): 835.","DOI":"10.3390\/diagnostics14080835"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_023","doi-asserted-by":"crossref","unstructured":"M\u00d8LLER S, BERNARDI M. Interactions of the heart and the liver [J]. Eur Heart J, 2013, 34(36): 2804\u201311.","DOI":"10.1093\/eurheartj\/eht246"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_024","doi-asserted-by":"crossref","unstructured":"M\u00d8LLER S, HENRIKSEN J H. Cirrhotic cardiomyopathy [J]. J Hepatol, 2010, 53(1): 179\u201390.","DOI":"10.1016\/j.jhep.2010.02.023"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_025","doi-asserted-by":"crossref","unstructured":"TIMOH T, PROTANO MA, WAGMAN G, BLOOM M, VITTORIO TJ. A perspective on cirrhotic cardiomyopathy [J]. Transplant Proc, 2011, 43(5): 1649\u201353.","DOI":"10.1016\/j.transproceed.2011.01.188"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_026","doi-asserted-by":"crossref","unstructured":"KALAMBOKIS G, CHRISTAKI M, TSIAKAS I, DESPOTIS G, LAKKAS L, TSIOURIS S, XOURGIA X, MARKOPOULOS GS, DOVA L, MILIONIS H. Association of left ventricular diastolic dysfunction with inflammatory activity, renal dysfunction, and liver-related mortality in patients with cirrhosis and ascites [J]. Eur J Gastroenterol Hepatol, 2024, 36(6): 775\u201383.","DOI":"10.1097\/MEG.0000000000002762"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_027","doi-asserted-by":"crossref","unstructured":"RU\u00cdZ-DEL-\u00c1RBOL L, ACH\u00c9CAR L, SERRADILLA R, RODR\u00cdGUEZ-GAND\u00cdA M, RIVERO M, GARRIDO E, NATCHER JJ. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension, and a normal creatinine [J]. Hepatology, 2013, 58(5): 1732\u201341.","DOI":"10.1002\/hep.26509"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_028","doi-asserted-by":"crossref","unstructured":"M\u00d8LLER S, WIESE S, HALGREEN H, HOVE JD. Diastolic dysfunction in cirrhosis [J]. Heart Fail Rev, 2016, 21(5): 599\u2013610.","DOI":"10.1007\/s10741-016-9552-9"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_029","doi-asserted-by":"crossref","unstructured":"LEE SS, LIU H. Cardiovascular determinants of survival in cirrhosis [J]. Gut, 2007, 56(6): 746\u20138.","DOI":"10.1136\/gut.2006.112169"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_030","doi-asserted-by":"crossref","unstructured":"PREMKUMAR M, DEVURGOWDA D, VYAS T, SHASTHRY SM, KHUMUCKHAM JS, GOYAL R, THOMAS SS, KUMAR G. Left ventricular diastolic dysfunction is associated with renal dysfunction, poor survival and low health related quality of life in cirrhosis [J]. J Clin Exp Hepatol, 2019, 9(3): 324\u201333.","DOI":"10.1016\/j.jceh.2018.08.008"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_031","doi-asserted-by":"crossref","unstructured":"PREMKUMAR M, RANGEGOWDA D, VYAS T, KHUMUCKHAM JS, SHASTHRY SM, THOMAS SS, GOYAL R, KUMAR G, SARIN SK. Carvedilol combined with ivabradine improves left ventricular diastolic dysfunction, clinical progression, and survival in cirrhosis [J]. J Clin Gastroenterol, 2020, 54(6): 561\u20138.","DOI":"10.1097\/MCG.0000000000001219"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_032","doi-asserted-by":"crossref","unstructured":"TRIPATHI D, HANDLEY K, HOLDEN L, ABDALI Z, JOWETT S, MATHERS J, POYNER C, RICHARDSON P, FERGUSON J, ROWE I. Clinical trial: a multicentre randomised controlled trial of carvedilol versus variceal band ligation in primary prevention of variceal bleeding in liver cirrhosis (CALIBRE Trial) [J]. Aliment Pharmacol Ther, 2025, 61(11): 1740\u201354.","DOI":"10.1111\/apt.70080"},{"key":"2026060512262507672_j_rjim-2025-0022_ref_033","doi-asserted-by":"crossref","unstructured":"BERZIGOTTI A. Optimizing non-invasive monitoring of the therapeutic response to NSBBs in portal hypertension: is machine learning the answer? [J]. Hepatol Int, 2025, 19(2): 302\u20133.","DOI":"10.1007\/s12072-025-10804-8"}],"container-title":["Romanian Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/rjim-2025-0022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:27:04Z","timestamp":1780662424000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/rjim-2025-0022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,19]]},"published-print":{"date-parts":[[2026,3,1]]}},"alternative-id":["10.2478\/rjim-2025-0022"],"URL":"https:\/\/doi.org\/10.2478\/rjim-2025-0022","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}